SEARCH:   Advanced

Blood, 15 February 2004, Vol. 103, No. 4, pp. 1495-1498. Prepublished online as a Blood First Edition Paper on October 23, 2003; DOI 10.1182/blood-2003-01-0154. This Article Full Text (PDF) All Versions of this Article: 2003-01-0154v1 103/4/1495    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wassmann, B. Articles by Ottmann, O. G Search for Related Content PubMed PubMed Citation Articles by Wassmann, B. Articles by Ottmann, O. G Social Bookmarking                   What's this? Submitted January 30, 2003 Accepted August 28, 2003 Early prediction of response in patients with relapsed or refractory Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib mesylate (Glivec) Barbara Wassmann, Heike Pfeifer, Urban J Scheuring, Anja Binckebanck, Nicola Goekbuget, Johannes Atta, Patrick Brueck, Harald Rieder, Claudia Schoch, Lothar Leimer, Rainer Schwerdtfeger, Gerhard Ehninger, Thomas Lipp, Jolanta Perz, Matthias Stelljes, Harald Gschaidmeier, Dieter Hoelzer, and Oliver G Ottmann* Medizinische Klinik III, Department of Hematology and Oncology, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany Department of Cytogenetics, University of Marburg, Marburg, Germany Department of Hematology and Oncology, Ludwig Maximilians University, Klinikum Grosshadern, Munich, Germany Department of Hematology and Oncology, Robert Bosch Krankenhaus, Stuttgart, Germany Department of Bone Marrow Transplantation, Deutsche Klinik fuer Diagnostik, Wiesbaden, Germany Department of Hematology and Oncology, University Carl Gustav Carus, Dresden, Germany Department of Hematology and Oncology, Klinikum Muenchen Schwabing, Munich, Germany Department of Hematology and Oncology, University Heidelberg, Heidelberg, Germany Department of Hematology and Oncology, University Muenster, Muenster, Germany Novartis Pharma GmbH, Nuernberg, Germany * Corresponding author; email: ottmann{at}em.uni-frankfurt.de. Imatinib has pronounced but brief antileukemic activity in advanced Ph+ALL. We assessed the prognostic impact of pretreatment disease features and the early bone marrow (BM) response in 68 consecutive Ph+ALL patients receiving imatinib salvage therapy. 92% of patients with BM blasts below 5% on day 14 achieved a complete hematologic or marrow response, whereas 62.5% of patients with >5% d14 BM blasts were non-responders. Similarly, time to progression (TTP) was superior in patients with a good d14 response (5.2 versus 0.9 months, p<0.0001). Prior CR of <6 months, WBC >10x109/L, circulating PB blasts at diagnosis, additional Philadelphia chromosomes or 2 Bcr-Abl fusion signals were associated with significantly inferior remission rate and response duration. In patients without poor prognostic features, single-agent imatinib may be appropriate pre-transplant salvage therapy. Conversely, patients with clinically or cytogenetically defined poor risk features are candidates for trials of up-front imatinib in combination with other agents. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, R. A. Larson, G. Rege-Cambrin, J. Radich, A. Hochhaus, A. M. Apanovitch, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood, October 1, 2007; 110(7): 2309 - 2315. [Abstract] [Full Text] [PDF] H. Pfeifer, B. Wassmann, A. Pavlova, L. Wunderle, J. Oldenburg, A. Binckebanck, T. Lange, A. Hochhaus, S. Wystub, P. Bruck, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood, July 15, 2007; 110(2): 727 - 734. [Abstract] [Full Text] [PDF] B. Wassmann, H. Pfeifer, N. Goekbuget, D. W. Beelen, J. Beck, M. Stelljes, M. Bornhauser, A. Reichle, J. Perz, R. Haas, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) Blood, September 1, 2006; 108(5): 1469 - 1477. [Abstract] [Full Text] [PDF] B. Wassmann, H. Pfeifer, M. Stadler, M. Bornhauser, G. Bug, U. J. Scheuring, P. Bruck, M. Stelljes, R. Schwerdtfeger, N. Basara, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood, July 15, 2005; 106(2): 458 - 463. [Abstract] [Full Text] [PDF] S. Lee, Y.-J. Kim, C.-K. Min, H.-J. Kim, K.-S. Eom, D.-W. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, May 1, 2005; 105(9): 3449 - 3457. [Abstract] [Full Text] [PDF] O. G. Ottmann and B. Wassmann Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Hematology, January 1, 2005; 2005(1): 118 - 122. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020